Cargando…
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
LESSONS LEARNED: Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Desp...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/ https://www.ncbi.nlm.nih.gov/pubmed/27694157 http://dx.doi.org/10.1634/theoncologist.2016-0220 |
_version_ | 1782459617961312256 |
---|---|
author | Chiappori, Alberto A. Otterson, Gregory A. Dowlati, Afshin Traynor, Anne M. Horn, Leora Owonikoko, Taofeek K. Ross, Helen J. Hann, Christine L. Abu Hejleh, Taher Nieva, Jorge Zhao, Xiuhua Schell, Michael Sullivan, Daniel M. |
author_facet | Chiappori, Alberto A. Otterson, Gregory A. Dowlati, Afshin Traynor, Anne M. Horn, Leora Owonikoko, Taofeek K. Ross, Helen J. Hann, Christine L. Abu Hejleh, Taher Nieva, Jorge Zhao, Xiuhua Schell, Michael Sullivan, Daniel M. |
author_sort | Chiappori, Alberto A. |
collection | PubMed |
description | LESSONS LEARNED: Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Despite lack of a reliable predictive biomarker in this disease, which may have partly contributed to the negative outcome reported here, linsitinib, although safe, showed no clinical activity in unselected, relapsed SCLC patients. BACKGROUND. Treatment of relapsed small-cell lung cancer (SCLC) remains suboptimal. Insulin growth factor-1 receptor (IGF-1R) signaling plays a role in growth, survival, and chemoresistance in SCLC. Linsitinib is a potent IGF-1R tyrosine kinase inhibitor that potentially may be active against SCLC. METHODS. In this phase II study, 8 eligible patients were randomly assigned in a 1:2 ratio to topotecan (1.5 mg/m(2) intravenously or 2.3 mg/m(2) orally, daily for 5 days for 4 cycles) or linsitinib (150 mg orally twice daily until progression). The primary endpoint was progression-free survival. Patients with relapsed SCLC, platinum sensitive or resistant, performance status (PS) 0–2, and adequate hematologic, renal, and hepatic function were enrolled. Patients with diabetes, cirrhosis, and those taking insulinotropic agents were excluded. Crossover to linsitinib was allowed at progression. RESULTS. Fifteen patients received topotecan (8 resistant, 3 with PS 2) and 29 received linsitinib (16 resistant, 5 with PS 2). Two partial responses were observed with topotecan. Only 4 of 15 patients with topotecan and 1 of 29 with linsitinib achieved stable disease. Median progression-free survival was 3.0 (95% confidence interval [CI], 1.5–3.6) and 1.2 (95% CI, 1.1–1.4) months for topotecan and linsitinib, respectively (p = .0001). Median survival was 5.3 (95% CI, 2.2–7.6) and 3.4 (95% CI, 1.8–5.6) months for topotecan and linsitinib, respectively (p = .71). Grade 3/4 adverse events (>5% incidence) included anemia, thrombocytopenia, neutropenia/leukopenia, diarrhea, fatigue, dehydration, and hypokalemia for topotecan; and thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations for linsitinib. CONCLUSION. Linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients. |
format | Online Article Text |
id | pubmed-5061534 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | AlphaMed Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50615342016-10-13 A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer Chiappori, Alberto A. Otterson, Gregory A. Dowlati, Afshin Traynor, Anne M. Horn, Leora Owonikoko, Taofeek K. Ross, Helen J. Hann, Christine L. Abu Hejleh, Taher Nieva, Jorge Zhao, Xiuhua Schell, Michael Sullivan, Daniel M. Oncologist Clinical Trial Results LESSONS LEARNED: Targeted therapy options for SCLC patients are limited; no agent, thus far, has resulted in a strategy promising enough to progress to phase III trials. Linsitinib, a potent insulin growth factor-1-receptor tyrosine kinase inhibitor, may be one agent with activity against SCLC. Despite lack of a reliable predictive biomarker in this disease, which may have partly contributed to the negative outcome reported here, linsitinib, although safe, showed no clinical activity in unselected, relapsed SCLC patients. BACKGROUND. Treatment of relapsed small-cell lung cancer (SCLC) remains suboptimal. Insulin growth factor-1 receptor (IGF-1R) signaling plays a role in growth, survival, and chemoresistance in SCLC. Linsitinib is a potent IGF-1R tyrosine kinase inhibitor that potentially may be active against SCLC. METHODS. In this phase II study, 8 eligible patients were randomly assigned in a 1:2 ratio to topotecan (1.5 mg/m(2) intravenously or 2.3 mg/m(2) orally, daily for 5 days for 4 cycles) or linsitinib (150 mg orally twice daily until progression). The primary endpoint was progression-free survival. Patients with relapsed SCLC, platinum sensitive or resistant, performance status (PS) 0–2, and adequate hematologic, renal, and hepatic function were enrolled. Patients with diabetes, cirrhosis, and those taking insulinotropic agents were excluded. Crossover to linsitinib was allowed at progression. RESULTS. Fifteen patients received topotecan (8 resistant, 3 with PS 2) and 29 received linsitinib (16 resistant, 5 with PS 2). Two partial responses were observed with topotecan. Only 4 of 15 patients with topotecan and 1 of 29 with linsitinib achieved stable disease. Median progression-free survival was 3.0 (95% confidence interval [CI], 1.5–3.6) and 1.2 (95% CI, 1.1–1.4) months for topotecan and linsitinib, respectively (p = .0001). Median survival was 5.3 (95% CI, 2.2–7.6) and 3.4 (95% CI, 1.8–5.6) months for topotecan and linsitinib, respectively (p = .71). Grade 3/4 adverse events (>5% incidence) included anemia, thrombocytopenia, neutropenia/leukopenia, diarrhea, fatigue, dehydration, and hypokalemia for topotecan; and thrombocytopenia, fatigue, and alanine aminotransferase/aspartate aminotransferase elevations for linsitinib. CONCLUSION. Linsitinib was safe but showed no clinical activity in unselected, relapsed SCLC patients. AlphaMed Press 2016-10 2016-09-30 /pmc/articles/PMC5061534/ /pubmed/27694157 http://dx.doi.org/10.1634/theoncologist.2016-0220 Text en ©AlphaMed Press; the data published online to support this summary is the property of the authors. |
spellingShingle | Clinical Trial Results Chiappori, Alberto A. Otterson, Gregory A. Dowlati, Afshin Traynor, Anne M. Horn, Leora Owonikoko, Taofeek K. Ross, Helen J. Hann, Christine L. Abu Hejleh, Taher Nieva, Jorge Zhao, Xiuhua Schell, Michael Sullivan, Daniel M. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title | A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title_full | A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title_fullStr | A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title_full_unstemmed | A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title_short | A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer |
title_sort | randomized phase ii study of linsitinib (osi-906) versus topotecan in patients with relapsed small-cell lung cancer |
topic | Clinical Trial Results |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/ https://www.ncbi.nlm.nih.gov/pubmed/27694157 http://dx.doi.org/10.1634/theoncologist.2016-0220 |
work_keys_str_mv | AT chiapporialbertoa arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT ottersongregorya arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT dowlatiafshin arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT traynorannem arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT hornleora arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT owonikokotaofeekk arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT rosshelenj arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT hannchristinel arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT abuhejlehtaher arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT nievajorge arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT zhaoxiuhua arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT schellmichael arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT sullivandanielm arandomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT chiapporialbertoa randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT ottersongregorya randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT dowlatiafshin randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT traynorannem randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT hornleora randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT owonikokotaofeekk randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT rosshelenj randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT hannchristinel randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT abuhejlehtaher randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT nievajorge randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT zhaoxiuhua randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT schellmichael randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer AT sullivandanielm randomizedphaseiistudyoflinsitinibosi906versustopotecaninpatientswithrelapsedsmallcelllungcancer |